TheraCea Pharma

TheraCea Pharma is a biotechnology company focused on advancing radiopharmaceuticals for precision medicine. The company has developed a proprietary chemical process for the rapid 18F-labeling of biologics, including peptides, proteins, and antibody fragments. By simplifying the preparation of these radiolabeled compounds, TheraCea’s technology overcomes traditional limitations in compounding and purification associated with the short half-life of Fluorine-18, enabling broader use in Positron Emission Tomography (PET) imaging for oncology, neurology, cardiology, and infectious diseases.

This technology provides clinicians with advanced diagnostic tools for the early detection of disease, staging, and evaluation of treatment responses, such as assessing the efficacy of immunotherapy. TheraCea aims to improve patient care by increasing the accessibility and reliability of PET diagnostic agents. Through collaborations with academic and clinical partners, as well as support from agencies like the National Science Foundation, the company seeks to accelerate the translation of its theranostic platforms from research settings into clinical applications to improve healthcare outcomes.